BHRT transdermal vs oral — what's different in practice?
Transdermal estradiol bypasses first-pass hepatic metabolism and carries a lower thrombotic risk signal. Oral estrogens are widely studied and convenient but raise SHBG and thrombotic risk. Modality is matched to risk profile and preference.
Full answer
Transdermal estradiol (patch, gel) bypasses first-pass hepatic metabolism and carries a lower venous thromboembolism risk signal than oral preparations; it is often preferred when thrombotic risk, hypertriglyceridemia, or migraine with aura is present. Oral estrogens raise SHBG and have a long evidence base; they remain reasonable in low-risk candidates with preference for that route. Progesterone choice (micronized preferred for sleep and breast-related risk signals) is reviewed in parallel. Every plan is synchronous-video reviewed.
Educational. Not a substitute for individualized provider review.
- BHRT Optimization pathway — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-06-03